Intercept pharmaceuticals, inc. (ICPT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Revenue

272,402

252,002

233,782

218,818

196,093

179,804

167,413

159,450

146,316

-

96,665

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

107,078

70,921

45,554

-

11,587

6,855

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of sales

4,490

4,212

2,745

2,777

2,813

2,519

2,335

1,988

1,554

1,371

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

338,749

317,418

294,709

274,693

270,234

255,474

268,838

273,382

275,083

273,698

265,577

257,023

238,813

273,596

257,770

229,710

201,969

119,242

70,712

55,106

42,087

34,601

27,471

21,450

16,386

13,132

10,585

8,461

6,514

5,177

4,029

4,192

4,142

4,209

0

0

0

Research and development

241,090

242,799

241,436

229,209

217,025

207,301

201,526

199,562

196,339

191,499

185,603

175,037

165,745

153,893

131,239

123,315

116,710

112,696

107,466

107,360

93,984

80,311

66,176

47,188

37,402

27,942

23,144

18,070

17,955

16,182

15,559

14,752

12,256

11,426

0

0

0

Total operating expenses

584,329

564,429

538,890

506,679

490,072

465,294

472,699

474,932

472,976

466,568

451,728

432,436

404,655

427,489

389,010

353,026

318,680

231,938

178,178

162,466

136,071

114,912

93,647

68,637

53,787

41,073

33,730

26,531

24,470

21,359

19,588

18,945

16,399

15,635

0

0

0

Operating loss

-311,927

-312,427

-305,108

-287,861

-293,979

-285,490

-308,488

-316,373

-327,105

-335,612

-344,650

-361,515

-359,101

-402,538

-340,315

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense):
Revaluation of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

170,832

169,262

190,018

251,385

28,441

5,823

-16,350

-21,621

-24,625

338

1,930

1,701

1,044

0

0

0

Interest expense

45,082

41,144

37,272

33,148

30,853

30,523

30,200

29,883

29,573

29,271

28,905

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

9,615

8,890

7,852

6,860

6,910

6,771

6,179

5,600

4,651

4,516

4,484

4,846

4,418

3,904

3,697

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency loss on liquidation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

437

330

-60

100

192

87

381

87

44

37

49

47

0

0

0

Total other (expense), net

-35,467

-32,254

-29,420

-26,288

-23,943

-23,752

-24,021

-24,283

-24,922

-24,755

-24,487

-23,836

-16,985

-10,292

-3,621

3,047

3,181

2,727

2,398

1,737

56,706

-170,056

-168,824

-189,687

-251,445

-28,341

-54,005

-34,771

-28,795

-24,729

190

1,775

1,750

1,092

0

0

0

Net loss

-347,394

-344,681

-334,528

-314,149

-317,922

-309,242

-332,509

-340,656

-352,027

-360,367

-369,137

-385,351

-376,086

-412,830

-381,042

-343,122

-313,717

-226,429

-172,999

-157,947

-76,583

-283,226

-260,769

-256,663

-303,610

-67,792

-86,114

-59,564

-51,173

-43,643

-16,598

-14,252

-12,084

-12,737

0

0

0

Net loss per common and potential common share:
Dividends on preferred stock, not declared

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,630

3,250

3,000

3,000

3,000

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-53,053

-46,273

-19,848

-17,252

-15,084

-15,737

0

0

0

Basic and diluted

-2.86

-2.99

-2.59

-2.28

-3.03

-2.88

-2.18

-2.58

-3.22

-4.42

-2.89

-3.46

-3.61

-4.84

-3.59

-3.14

-5.17

-3.69

-2.10

-1.99

-1.78

-

-1.69

-

-12.61

-

-1.65

-

-0.62

-2.02

-1.86

-1.75

-1.03

-1.32

-1.08

-1.10

-1.23

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1.60

-

-

-

-0.79

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1.51

-

-

-

-0.79

-

-

-

-

-

-

-

-

-

Weighted average common and potential common shares outstanding:
Basic and diluted

32,561

32,823

32,717

31,316

29,760

29,733

29,615

29,199

25,309

25,153

25,104

25,028

24,931

24,807

24,738

24,612

24,495

24,374

24,215

24,014

22,171

-

21,260

-

19,504

-

19,198

-

16,558

15,223

3,329

3,329

3,329

3,329

3,329

3,329

3,329

Weighted average shares outstanding, basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,965

-

-

-

16,970

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding, diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22,204

-

-

-

16,970

-

-

-

-

-

-

-

-

-

Other comprehensive gain (loss):
Unrealized gain (loss) on investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Total comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Product [Member]
Revenue

270,375

249,570

232,160

217,196

194,471

177,782

0

0

0

-

-

55,851

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License [Member]
Revenue

-

2,432

1,622

1,622

1,622

2,022

2,061

2,101

2,141

1,781

1,783

1,783

6,782

6,782

6,782

6,782

1,782

2,782

2,781

2,781

2,781

1,742

1,701

1,661

1,621

1,622

1,621

1,739

2,092

2,446

2,799

2,917

2,563

1,805

0

0

0